ArticleEuropean journal of clinical pharmacology2014
Effect of withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotic agents on cognition in older adults.
Article in European journal of clinical pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Development of a Coordinated, Community-Based Medication Management Model for Home-Dwelling Aged in Primary Care
Addressing Nocturnal Sleep/Wake Effects on Risk of Suicide in Older Adults (ANSWERS-OA): A Pilot, Open-Label, Randomized Controlled Trial of Digital Cognitive Behavioral Therapy for Insomnia
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis.British journal of clinical pharmacology · 2016Pooled it
- Enhanced coordination of care to reduce medication risks in older home care clients in primary care: a randomized controlled trial.BMC geriatrics · 2019Trial
- Long-term persistence of withdrawal of temazepam, zopiclone, and zolpidem in older adults: a 3-year follow-up study.BMC geriatrics · 2018Trial
- Handgrip strength and balance in older adults following withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotics.BMC geriatrics · 2014Trial
- Evoked craving in high-dose benzodiazepine users.Frontiers in psychiatry · 2025Article
- Brief Intervention as a Method to Reduce Z-Hypnotic Use by Older Adults: Feasibility Case Series.JMIR formative research · 2024Article
- Long-Term Use of Insomnia Medications: An Appraisal of the Current Clinical and Scientific Evidence.Journal of clinical medicine · 2023Review
- Pharmacopuncture Effects on Insomnia Disorder: Protocol for a Multi-Site, Randomized, Acupuncture-Controlled, Clinical Trial.International journal of environmental research and public health · 2022Article
- Current practice in benzodiazepine receptor agonists deprescribing on acute geriatric wards: a cohort study.BMC geriatrics · 2022Article
- Polysubstance Use Patterns Among High Dose Benzodiazepine Users: A Latent Class Analysis and Differences Between Male and Female Use.Frontiers in psychiatry · 2022Article
- Study protocol-Evoked craving in high-dose benzodiazepine users.Frontiers in psychiatry · 2022Article
- Detoxification Improves Multidomain Cognitive Dysfunction in High-Dose Benzodiazepine Abusers.Frontiers in neuroscience · 2020Article
- Emergency department visits involving benzodiazepines and non-benzodiazepine receptor agonists.The American journal of emergency medicine · 2017Article
- Cognitive behavioral therapy for insomnia helps to reverse cognitive impairment in insomnia patients.Sleep science (Sao Paulo, Brazil)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to assess the effect of withdrawal from the long-term use of temazepam, zopiclone or zolpidem as hypnotics drugs (here referred to as BZD) on cognitive performance.
methodsNinety-two adults (age ≥55 years) with primary insomnia and who were long-term daily users of BZD volunteered to participate in a 1-month medically supported withdrawal attempt from BZD use, with a subsequent 5-month follow-up. Withdrawal was based on plasma BZD measurements at baseline, at 1 month and during subsequent regular clinical appointments. Attention and psychomotor performance were measured using the CogniSpeed® at baseline and at 1, 2 and 6 months. Reaction times were determined in the Simple Reaction Time (SRT), Two-Choice Reaction Time (2-CRT) and Vigilance tests, and errors were measured by the 2-CRT and Vigilance tests. The cognition data of the withdrawal group were also compared with a cohort of BZD non-users.
resultsEighty-nine (97 %) participants (59 women, 30 men) were followed-up for a maximum of 6 months. During the follow-up period, changes in reaction times and errors did not differ between short-term withdrawers (no residual BZD at 1 month; N = 69), non-withdrawers (residual BZD at 1 month; N = 20) or long-term withdrawers (N = 34). Compared to the reaction times of the BZD-free cohort, those of BZD users were slower at baseline. The reaction times of BZD withdrawers based on the results of the SRT or 2-CRT tests during follow-up did not reach those of the BZD-free cohort, but there was no difference between these groups in the Vigilance test.
conclusionsLong-term use of BDZ as hypnotic drugs by older adults is related to prolonged impairment of attentional and psychomotor cognitive functioning that persists for at least 6 months after withdrawal.
Indexed as
Identifiers
24337417What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.